Gomes Aldrin V, Young Glen W, Wang Yueju, Zong Chenggong, Eghbali Mansoureh, Drews Oliver, Lu Haojie, Stefani Enrico, Ping Peipei
Department of Physiology and Medicine, Cardiac Proteomics and Signaling Laboratory at Cardiovascular Research Laboratory, University of California Los Angeles, School of Medicine, Los Angeles, CA 90095, USA.
Mol Cell Proteomics. 2009 Feb;8(2):302-15. doi: 10.1074/mcp.M800058-MCP200. Epub 2008 Oct 17.
The 20 S proteasome complexes are major contributors to the intracellular protein degradation machinery in mammalian cells. Systematic administration of proteasome inhibitors to combat disease (e.g. cancer) has resulted in positive outcomes as well as adversary effects. The latter was attributed to, at least in part, a lack of understanding in the organ-specific responses to inhibitors and the potential diversity of proteomes of these complexes in different tissues. Accordingly, we conducted a proteomic study to characterize the 20 S proteasome complexes and their postulated organ-specific responses in the heart and liver. The cardiac and hepatic 20 S proteasomes were isolated from the same mouse strain with identical genetic background. We examined the molecular composition, complex assembly, post-translational modifications and associating partners of these proteasome complexes. Our results revealed an organ-specific molecular organization of the 20 S proteasomes with distinguished patterns of post-translational modifications as well as unique complex assembly characteristics. Furthermore, the proteome diversities are concomitant with a functional heterogeneity of the proteolytic patterns exhibited by these two organs. In particular, the heart and liver displayed distinct activity profiles to two proteasome inhibitors, epoxomicin and Z-Pro-Nle-Asp-H. Finally, the heart and liver demonstrated contrasting regulatory mechanisms from the associating partners of these proteasomes. The functional heterogeneity of the mammalian 20 S proteasome complexes underscores the concept of divergent proteomes among organs in the context of an identical genome.
20S蛋白酶体复合物是哺乳动物细胞内蛋白质降解机制的主要贡献者。系统性施用蛋白酶体抑制剂来对抗疾病(如癌症)已产生了积极效果以及不良影响。后者至少部分归因于对抑制剂的器官特异性反应以及这些复合物在不同组织中蛋白质组潜在多样性缺乏了解。因此,我们进行了一项蛋白质组学研究,以表征心脏和肝脏中的20S蛋白酶体复合物及其假定的器官特异性反应。从具有相同遗传背景的同一小鼠品系中分离出心脏和肝脏的20S蛋白酶体。我们研究了这些蛋白酶体复合物的分子组成、复合物组装、翻译后修饰和相关伴侣。我们的结果揭示了20S蛋白酶体的器官特异性分子组织,具有独特的翻译后修饰模式以及独特的复合物组装特征。此外,蛋白质组多样性与这两个器官所表现出的蛋白水解模式的功能异质性相伴。特别是,心脏和肝脏对两种蛋白酶体抑制剂环氧霉素和Z-Pro-Nle-Asp-H表现出不同的活性谱。最后,心脏和肝脏在这些蛋白酶体的相关伴侣方面表现出相反的调节机制。哺乳动物20S蛋白酶体复合物的功能异质性强调了在相同基因组背景下各器官蛋白质组不同的概念。